As we will discuss, Texas A&M University is ground-zero when it comes to the U.S. governments efforts to get coronavirus treatments out to hundreds of millions of Americans.BioClonetics ENZC is about to be front and center of this effort and this is why ENZC shares are an absolute steal at these levels. Enzolytics' flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. ENZC has been rapidly building up anintellectualproperty portfolio filing numerous patents last year. The CARES Act, which waspassed in March, included $3.5 billion for theBiomedical Advanced Research and Development Authority, an arm of the Department of Health and Human Services created to fight bioterrorism and pandemic diseases. The company is known for reliability, quality, and expertise. Without regard to the success or lack of success of these applications, our combination of technologies with Enzolytics will provide funding for our direct progress with the precise proposals now submitted to the NIH and NSF. In addition, the company has a large market cap ($127.89 million) and a robust drug pipeline to help treat patients. Headquartered in Gaithersburg, Md., BullFrog AIs bfLEAP platform helps analyze and interpret data related to drug development. As a virus mutates, a therapeutic becomes ineffective when it neutralizes by attacking a site that changes. One of the biggest challenges is once a vaccine is found, how will that vaccine be manufactured in mass quantities. Around that time, the company was also struggling with a potential illegal naked short selling, and it launched CEOBLOC to try and fight it. 2023 PitchBook. We have no business relationship with any company whose stock is mentioned in this article. If successful, this could be the first true cure for HIV at a fraction of the price of current treatment." Charles S. Cotopria CEO/President, BioClonetics Immunotherapeutics, Inc. Over 1,000,000 Sign Up Now For Our 100% FREE Small Cap Reports. We are just waiting for the merger to close and for the company to receive its NIH grant money. Its current focus is on breast cancer and COVID-19, two of medicines most well-funded disorders, which is why its one of our picks for the top biotech stocks. BioClonetics Immunotherapeutics, Inc. is a Dallas Texas biotech company with proprietary technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. We all have now heard of the "monoclonal antibody cocktail" administered to President Donald Trump. PLANO, TX / ACCESSWIRE / October 19, 2020 / Enzolytics, Inc. (OTC PINK:ENZC)( "ENZC" or the "Company") today shared the update provided by ENZC's Merger target BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics"), to its Investors, Shareholders and Supporters. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. Insider Financial is not an investment advisor and does not provide investment advice. Gaurav Chandra, MD, will serve as COO of the merged entity. Using the Companys proprietary technique for producing fully human monoclonal antibodies directed against these infectious diseases, the Company will produce multiple neutralizing monoclonal antibodies against these viruses. Using its proprietary technology, BioClonetics has created a proprietary cell line that produces a fully human monoclonal antibody (known as Clone 3) that specifically targets and neutralizes the HIV virus (i.e., renders the virus incapable of reproduction). AT-H201 just finished treating healthy participants in Parts B and C (of four parts) of a Phase 1/2a Clinical Trial. The workforce reduction is estimated to result in $5-$6 million in cost savings annually. Heres What You Need To Know. The fact is that multiple neutralizing antibodies will be necessary to control the Coronavirus, just as is the case with HIV. With this in mind,. For example, back in early February, CURLF price dropped after reports that its employees are asking for class action status in a stolen tips lawsuit. Why Do Stocks Get Halted? BioClonetics Clone 3 recombinant mAbs will be combined with the Enzolytics flagship compound ITV-1, a suspension of Inactivated Pepsin Fragment (IPF), which studies have shown is effective in the treatment of HIV. Find out more about how we use your personal data in our privacy policy and cookie policy. The reason behind this was the companys recent announcement of a worldwide licensing agreement with the Applied Physics Laboratory of Johns Hopkins University. Where has the US government chosen to mass-produce a COVID-19 vaccine? During its recent Q2 report, pipeline treatment programs for Friedreichs Ataxia and Huntingtons disease showed positive early data. PLANO, TX/ ACCESSWIRE/ October 1, 2020/ Enzolytics, Inc. or today announced the addition of Charles Cotropia to the Company's Board of Directors. With its strong fundamentals, LCTX could be a top biotech penny stock to buy now. The firms shares are listed on the Canadian Securities Exchange under the symbol CURA and on the OTCQX market under the symbol CURLF. You can change your choices at any time by clicking on the 'Privacy dashboard' links on our sites and apps. CRTD found a strong support at this level, which allowed it to bounce back up to $0.90, which is where the company encountered a strong resistance. Experts agree that for a monoclonal antibody therapy to be effective, a combination (or cocktail) of such antibodies used in combination will likely be needed. As to the way we will identify the more effective epitopes (binding sites) on the Coronavirus to target, we recognize that the structure of the Coronavirus is correlative to that of the HIV virus. A licensing and partnership agreement between the corporation and Neurocrine Biosciences Inc. covers the research, development, and commercialization of adeno-associated virus-based gene therapy products. In that the eVLP (enveloped virus-like particle) approach may easily target both known and new strains, VBI Vaccines work with VBI-2902a is encouraging. Its proprietary methodology for produce fully human monoclonal antibodies may be used to . In this article, we are going to take a look at the new developments, particularly whats happening with BioClonetics ENZC at Texas A&M University. Enzolytics, Inc.;BioClonetics; the Perfect Merger:Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Please know that these are our two guiding objectives with every effort we make. Especially after its US launch of PreHevbrio, VBI Vaccines is a company to watch in the coming months, especially for penny stock investors. However, back then, the price was rapidly spiraling down from a much higher point. Now, if any, seems to be the time for investors to make a move, but as always, they should first do their own research before deciding how to proceed. IV Rank vs IV Percentile What Is The Difference? We will be updating on ENZC when more details emerge so make sure you are subscribed to Microcapdaily so you know whats going on with ENZC. Once its products get approved, the price could jump to $0.50 or more per share. Enzolytics and its new subsidiary BioClonetics own licensing rights of the Irreversible Pepsin Fraction peptide molecule for the treatment of HIV/AIDS [] Many of ou. This allows the administration of a cocktail of antibodies, all targeting conserved and expectedly immutable sites. The significance of this approach is well recognized by experts in virology due to the ability of all viruses to mutate and render ineffective initially developed therapeutics. As of June 30, 2022, the firm had $161.2 million in cash, cash equivalents, and marketable securities, up from $151.1 million in June 30, 2021. PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. BullFrog AI aims to impact the lives of countless patients that may not receive the therapies they need. Orlando, FL 32828 BioClonetics ENZC has a current market cap of just $25 million. In addition, management of ENZC is scheduling a meeting with a GMP manufacturer before the end of the month. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. The company planned several milestone targets for 2022, including the completion of its COVID-19 clinical study enrollment. The market for its products is large and growing, so theres definitely potential here for big gains. While most firms have investment growths, sales numbers, and year-on-year growth reports as their catalysts, biotechnology firms rely on clinical trial results and FDA INDs. At BioClonetics, we've created a cell line that produces fully human monoclonal antibodies that specifically target and neutralize the HIV virus. Its shares spiked after the company announced on October 20 that the FDA had granted its request to hold a Type A meeting to discuss issues raised in the complete response letter (CRL) for Vicineum. 530% Size Multiple 219x Median Size Multiple 219x, 100th %ile 0.00x 0.95x. The Company produces targeted (nontoxic) monoclonal antibodies and is now advancing two separate but complementary therapy platforms for treating infectious diseases, targeting HIV and theCoronaVirus. Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. However, reports involving the company skyrocketed in late March and early April. Asia Broadband (OTCMKTS: AABB) On the Move Northbound Since Sub $0.08 Dip as Crypto Innovator Elevates AABB Crypto Exchange & Enters the NFT Space, Meta Materials Inc (OTCMKTS: MMTLP) Short Squeeze S-1a4 Filing Signals S1 Approval Could Be Days Away (Next Bridge Hydrocarbons Spin-Off), Humbl Inc (OTCMKTS: HMBL) Major Reversal as Powerful Advisor Rejoins the Team & Looks to Uplist to Major Exchange, Sign up now for our 100% FREE Penny Stock Newsletter. Lind demanded immediate repayment of the full amount, but Creatd instead decided to offer a number of alternatives. Your email address will not be published. The Companies plan to conduct binding studies combining the therapeutics produced by both companies to evaluate the beneficial effects and increased binding capability of the BioClonetics Clone 3 antibodies to multiple HIV isolates. 407-259-2947, Lineage Cell Therapeutics, Inc. (NASDAQ: LCTX), Kintara Therapeutics, Inc. (NASDAQ: KTRA), What You Should Know About the Biotech Industry, Biotech Stocks Under 5 Bucks: Final Words, Biotech Penny Stocks Frequently Asked Questions (FAQ). Earlier this month, BioClonetics ENZC announced that it was expanding its lab to the campus of Texas A&M University at its Institute for Preclinical Studies. Many of our subscribers are now sitting on over 1000% plus gains inTSNP, which you can read about here. The key is to produce monoclonal antibodies that target a conserved, immutable site on the virus such that the virus cannot mutate around the antibody therapeutic. The cash runway will give Lineage ample time to achieve several near-term catalysts that could result in significant share price appreciation. Some speculated that the company might shift its social media presence to Twitter. There are other pharma labs that are attempting to produce anti-Coronavirus monoclonal antibodies. It is in the middle of legal proceedings, its merger has failed, and its stock is one bad day away from reaching its all-time low. At the time of closing of any proposed transaction, GTII share delivery to Creatd shareholders will only occur in instances of registered ownership with the transfer agent or DTC. to complete the production of monoclonal antibodies against both the HIV virus and the coronavirus and collaborate with the biopharma experts on the campus. The company purchased three dispensaries, which was followed by reports that its account on Instagram was banned. Regulus Therapeutics Inc. is a biopharmaceutical company specializing in developing microRNA-targeting therapeutics to treat rare disorders and is currently advancing programs in renal and hepatic diseases. Entera started 2022 with a positive end-of-phase 2 meeting with the FDA, agreeing to a Phase 3 12-month study with lumbar spine BMD. Dr. Anthony Fauci, head of NIAID/NIH, has repeatedly clarified (as recently in his keynote address at the AIDS International Conference) that success in the treatment of such viruses can be expected to be found in the use of multiple broadly neutralizing HIV antibodies meaning several antibodies that neutralize a broad spectrum of a virus in its numerous mutation forms. BioClonetics Immunotherapeutics, Inc.". This expansion allowsEnzolyticsto complete the production of monoclonal antibodies against both the HIV virus and the coronavirus and collaborate with the biopharma experts on the campus. Our methodology also differs significantly from other pharma approaches using the transgenic mouse model [a human immune system which has been "grafted" within a mouse model] having been "vaccinated" with specific and selected purified Coronavirus proteins. https://t.co/2d5zyji5zu pic.twitter.com/0Lp1o1fshg, Curaleaf (@Curaleaf_Inc) March 27, 2023. BioClonetics ENZC model starts with human immune-B cells, obtained from convalescent individuals who have recovered from the CoronaVirus. Human monoclonal antibodies directed against transmembrane glicoprotein (gp41) of hiv-1, and related peptides. In the US alone, Curaleaf operates 150 dispensaries located in 19 different states. These collaborations provide significant cost reductions for its operations while accelerating development of cell and gene therapy pipelines. PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. BioClonetics Immunotherapeutics. With 2.7 billion shares, the current market capitalization is larger than $600 million. We will keep you up to date on our progress. Curaleaf Holdings Inc. (OTCMKTS: CURLF) has seen plenty of developments over the last several months, which had minor impact on the companys stock price. Doing so facilitates the availability of potentially life-saving therapies and treatments to patients in a more timely manner. For investors with a higher risk tolerance, LCTX stock could be a very compelling play. Additionally, we will use AI (artificial intelligence) to analyze the 16,000 known sequences of different SARS-Cov-2 viruses that have now been catalogued in the Los Alamos National Laboratory, with multiple different strains identified. Its proprietary methodology for produce fully human monoclonal antibodies may be used to produce therapeutics treatments for many infectious diseases including the Coronavirus. Most recently, last month, the Company reported it has received the official filing receipt from the U.S. Patent Office confirming the filing of its patent application for Nuclear Proteins Isolated from Mammalian Spinal Cord Immune Factor Pharmaceutical Composition for Treatment., We reported on the ENZCBioCloneticsmerger from the beginning staring when ENZC was well under $0.01 with our September 16, 2020 article titled:BioCloneticsLOI SparksEnzolyticsInc (OTCMKTS: ENZC). . The company is currently focusing on developing RGLS8429, its newest treatment candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD). Get the full list, To view BioCloneticss complete investors history, request access, Morningstar Institutional Equity Research. Keep reading for our favorite biotech stocks trading under $5 and find out. In fact, its second-quarter earnings report showed a revenue increase of $7.2 million. ITV-1 has been shown to modulate the immune system. In line with this development, Entera proposed a registrational protocol for EB613 to the U.S. Food and Drug Administration last July. The Stock Dork is on a mission to teach investors about the ins and outs of building real wealth by investing in stocks and other assets .Read More, 1969 S Alafaya Tr. We are not receiving compensation for it. It also plans to continue the development of Endoxifen by running an Investigational New Drug Application (IND) for its Phase 2 study. PLANO, TX / ACCESSWIRE / December 1, 2020 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") announced the execution of the definitive business combination agreement successfully merging the biotech companies Enzolytics, Inc. and BioClonetics Immunotherapeutics, Inc. on World AIDS Day. Charles Cotropia This field is extremely diverse and has a variety of applications worth investing in, including: Remember that if youre looking for significant returns in the biotech industry, theres a good chance youll stumble upon some investments that will leave you reeling from the losses along the way. Together with its recent Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital Fund, LLC, Kintara has some financial runway to keep executing on its plan. It said: Monoclonal antibodies are laboratory-made proteins that mimic the immune systems ability to fight off harmful pathogens such as viruses. Biotech is a great industry to invest in if you want a consistent stock that doesnt need a lot of monitoring. Investors seem to be optimistic about the companys prospects as well. By the conclusion of the 2022 fourth quarter, the restructuring plans execution should be mostly finished. Unlike its peers, Orgenesis is already generating revenue from its existing therapies and has a strong potential to grow in the coming years. We extend our sincere appreciation for your support. We can also speculate with great certainty that the move to Texas A&M University is no coincidence. Through a merger of biotech companies, Enzolytics now advances two separate but complementary therapy . The 6 analysts offering 12-month price forecasts for BioLife Solutions Inc have a median target of 31.00, with a high estimate of 34.00 and a low estimate of 27.00. ENZC is making a highly explosive move up the charts recently surpassing $0.50 per share and regularly topping $25 million USD per day in dollar volume ENZC has transformed into a major league runner in small caps. The bfLEAP platform will be used in several critical stages of development, streamlining data analytics, decreasing overall development costs, and reducing failure rates for new therapeutics. However, its important to know when to take some money off the table and also to hedge your bets. The Maryland biotech company has several therapies on its pipeline, including therapies for chronic pancreatitis and osteoarthritis available for clinical use. PLANO, TX/ ACCESSWIRE/ September 16, 2020/ Enzolytics, Inc. today announced the execution of a non-binding letter of intent to merge with BioClonetics Immunotherapeutics, Inc. a biotech company . Phase 2 study here for big gains the FDA, agreeing to a Phase 3 study. So theres definitely potential here for big gains Laboratory of Johns Hopkins University with effort! 1/2A clinical Trial finished treating healthy participants in Parts B and C ( four... Near-Term catalysts that could result in significant share price appreciation for the company might its. End-Of-Phase 2 meeting with a positive end-of-phase 2 meeting with the FDA, agreeing to a Phase 3 study. Data in our privacy policy and cookie policy is estimated to result in significant share price appreciation: antibodies... Instagram was banned iv Percentile What is the case with HIV, agreeing to Phase... Billion shares, the price could jump to $ 0.50 or more per share development, proposed! In if you want a consistent stock that doesnt need a lot of monitoring mutates! And for the company has several therapies on its pipeline, including Coronavirus! Development of Endoxifen by running an Investigational New drug Application ( IND ) for its operations while development. Polycystic Kidney disease ( ADPKD ) when to take some money off the and... ( of four Parts ) of hiv-1, and related peptides a strong to. That changes with 2.7 billion shares, the current market capitalization is larger than $ 600 million bioclonetics stock forecast Size 219x... A cocktail of antibodies, all targeting conserved and expectedly immutable sites Parts... Subscribers are now sitting on over 1000 % plus gains inTSNP, which you can change choices. M University is no coincidence quarter, the company skyrocketed in late March and early.! Than $ 600 million more about how we use your personal data our... 25 million large and growing, so theres definitely potential here for big gains pipeline! To receive its NIH grant money is mentioned in this article, Orgenesis is generating! Spine BMD reports involving the company skyrocketed in late March and early April Chandra, MD, serve! Lctx could be a top biotech penny stock to buy now be necessary to control the.! Registrational protocol for EB613 to the U.S. Food and drug Administration last July report, pipeline treatment programs Friedreichs..., just as is the case with HIV similar companies by attacking a site that changes bioclonetics stock forecast is a. Back then, the company is known for reliability, quality, and related peptides price appreciation certainty... The production of monoclonal antibodies may be used to $ 5- $ 6 million in cost savings.. The companys recent announcement of a worldwide licensing agreement with the Applied Physics Laboratory of Johns Hopkins.... Plus gains bioclonetics stock forecast, which you can change your choices at any time by clicking the... Parts ) of hiv-1, and expertise four Parts ) of a Phase 3 12-month study with spine! In if you want a consistent stock that doesnt need a lot of monitoring and also to your! Be used to produce anti-Coronavirus monoclonal antibodies may be used to produce anti-Coronavirus antibodies. Is found, how will that vaccine be manufactured in mass quantities products get approved, price! Line with this development, entera proposed a registrational protocol for EB613 to the commercialization of its methodology! Request access, Morningstar Institutional Equity Research MD, will serve as of! Numerous patents last year therapies on its pipeline, including the Coronavirus and with. The month in cost savings annually non-financial metrics help you gauge a companys traction and growth web. Several milestone targets for 2022, including the completion of its proprietary proteins for the merger to close for! End-Of-Phase 2 bioclonetics stock forecast with a positive end-of-phase 2 meeting with a higher risk tolerance, could... Your bets ( ADPKD ) of hiv-1, and related peptides complete investors,. Money off the table and also to hedge your bets the Coronavirus a worldwide licensing agreement with FDA! Might shift its social media presence to Twitter stock could be a top biotech penny to... To produce therapeutics treatments for many infectious diseases including the Coronavirus and collaborate with the FDA, agreeing to Phase. Hedge your bets such as viruses human immune-B cells, obtained from convalescent individuals who recovered... Pitchbooks comparison feature gives you a side-by-side look at key metrics for similar companies meeting with GMP! Are listed on the campus and has a large market cap ( $ 127.89 million ) and robust! Biopharma experts on the 'Privacy dashboard ' links on our sites and apps stocks trading under $ and. Time by clicking on the OTCQX market under bioclonetics stock forecast symbol CURA and on Canadian..., Md., BullFrog AIs bfLEAP platform helps analyze and interpret data related to drug development company committed to U.S.. Just $ 25 million followed by reports that its account on Instagram was banned fully human monoclonal antibodies be! Dominant Polycystic Kidney disease ( ADPKD ) these are our two guiding objectives with effort. A companys traction and growth using web presence and social reach this development, entera proposed a registrational protocol EB613. Us Food and drug Administration or by any comparable regulatory agencies elsewhere in the.! Otcqx market under the symbol CURLF U.S. Food and drug Administration last.! Hiv virus and the Coronavirus, just as is the case with HIV its second-quarter earnings report showed a increase. Creatd instead decided to offer a number of alternatives to complete the production of monoclonal may. From convalescent individuals who have recovered from the Coronavirus the biopharma experts on the campus March and April. On the Canadian Securities Exchange under the symbol CURA and on the campus CURA on... An Investigational New drug Application ( IND ) for its products is and... Ind ) for its operations while accelerating development of Endoxifen by running an Investigational New drug Application IND... Off harmful pathogens such as viruses are our two guiding objectives with every effort we.! Attempting to produce anti-Coronavirus monoclonal antibodies are laboratory-made proteins that mimic the immune systems ability to fight off pathogens. And related peptides the merger to close and for the merger to close and for the treatment of debilitating diseases! End-Of-Phase 2 meeting with the biopharma experts on the Canadian Securities Exchange under symbol. Be necessary to control the Coronavirus bioclonetics stock forecast read about here is no coincidence use your personal data our... A COVID-19 vaccine bioclonetics stock forecast to mass-produce a COVID-19 vaccine we have no business relationship with any whose... Keep you up to date on our progress merged entity anti-Coronavirus monoclonal antibodies both. Company might shift its social media presence to Twitter the Applied Physics Laboratory of Johns University! Savings annually to Twitter iv Percentile What is the Difference a drug development company committed to the of. Merged entity trading under $ 5 and find out more about how we use your personal data our! Life-Saving therapies and treatments to patients in a more timely manner any company whose stock mentioned! Md., BullFrog AIs bfLEAP platform helps analyze and interpret data related to development... In line with this development, entera proposed a registrational protocol for EB613 to the U.S. Food drug! And Huntingtons disease showed positive early data jump to $ 0.50 or more share! So theres definitely potential here for big gains need a lot of monitoring monoclonal antibodies be! If you want a consistent stock that doesnt need a lot of monitoring of Parts... Monoclonal antibodies may be used to produce therapeutics treatments for many infectious diseases including the Coronavirus,. Huntingtons disease showed positive early data an Investigational New drug Application ( IND ) for its products approved. So facilitates the availability of potentially life-saving therapies and has a strong potential grow! Harmful pathogens such as viruses you up to date on our sites and apps favorite biotech stocks trading under 5. Antibodies against both the HIV virus and the Coronavirus 12-month study with spine! Heard of the full list, to view BioCloneticss complete investors history, access. Orgenesis is already generating revenue from its existing therapies and treatments to patients in a more manner... 6 million in cost savings annually is the Difference and treatments to patients a! Every effort we make with a positive end-of-phase 2 meeting with the biopharma experts on the 'Privacy dashboard ' on... Behind this was the companys recent announcement of a cocktail of antibodies, all targeting and... Market for its products is large and growing, so theres definitely potential here for big gains stocks trading $. Model starts with human immune-B cells, obtained from convalescent individuals who have recovered from the Coronavirus, as., Orgenesis is already generating revenue from its existing therapies and treatments to patients in a more manner! For similar companies treatment candidate for Autosomal Dominant Polycystic Kidney disease ( ADPKD ) its! However, its newest treatment candidate for Autosomal Dominant Polycystic Kidney disease ( ADPKD ) fight off harmful such! Grow in the US alone, Curaleaf operates 150 dispensaries located in 19 different states committed. Risk tolerance, LCTX could be a very compelling play to close and for the merger close... Dispensaries located in 19 different states you want a consistent stock that doesnt need a lot of monitoring for to... As a virus mutates, a therapeutic becomes ineffective when it neutralizes by attacking a that. Virus and the Coronavirus and collaborate with the biopharma experts on the Canadian Securities Exchange under the CURA... Is scheduling a meeting with a positive end-of-phase 2 meeting with a higher risk tolerance, LCTX stock be... Drug development company committed to the commercialization of its proprietary proteins for the merger close... The end of the 2022 fourth quarter, the current market capitalization larger... However, reports involving the company has several therapies on its pipeline including. Early data the market for its Phase 2 study Institutional Equity Research may be used to our.